- Home
- MIRM
MIRM
Mirum Pharmaceuticals Inc.
as 03-25-2025 12:35pm EST
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | N/A | IPO Year: | 2019 |
| Target Price: | $58.55 | AVG Volume (30 days): | 532.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.14 - $54.23 | Next Earning Date: | 05-07-2025 |
| Revenue: | $336,888,000 | Revenue Growth: | 80.76% |
| Revenue Growth (this year): | 27.25% | Revenue Growth (next year): | 21.81% |
Stock Insider Trading Activity of Mirum Pharmaceuticals Inc. (MIRM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Mar 18 '25 | Sell | $44.45 | 2,415 | $107,342.89 | 2,426 | |
| Heron Patrick J | MIRM | Director | Mar 14 '25 | Buy | $44.02 | 549 | $24,214.01 | 168,672 | |
| Heron Patrick J | MIRM | Director | Mar 10 '25 | Buy | $43.27 | 2,298 | $99,517.93 | 168,672 | |
| Heron Patrick J | MIRM | Director | Mar 6 '25 | Buy | $43.55 | 1,915 | $83,661.30 | 168,672 | |
| Heron Patrick J | MIRM | Director | Mar 4 '25 | Buy | $45.35 | 1,602 | $72,723.92 | 168,672 | |
| Radovich Peter | MIRM | PRESIDENT AND COO | Mar 4 '25 | Sell | $45.66 | 14,850 | $676,928.28 | 13,280 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Mar 3 '25 | Sell | $46.90 | 40,000 | $1,876,352.64 | 115,920 | |
| Radovich Peter | MIRM | PRESIDENT AND COO | Feb 3 '25 | Sell | $48.22 | 2,627 | $126,680.77 | 13,280 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Feb 3 '25 | Sell | $48.22 | 9,102 | $438,921.19 | 115,920 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Jan 31 '25 | Sell | $48.22 | 1,064 | $51,308.74 | 2,426 |
Latest Mirum Pharmaceuticals Inc. News
MIRM Breaking Stock News: Dive into MIRM Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Exploring 3 High Growth Tech Stocks in the US Market
Business Wire
15 days ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
21 days ago
Mirum Pharmaceuticals Insider Sold Shares Worth $676,928, According to a Recent SEC Filing
Simply Wall St.
25 days ago
Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report
Simply Wall St.
a month ago
Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations
Thomson Reuters StreetEvents
a month ago
Q4 2024 Mirum Pharmaceuticals Inc Earnings Call
Zacks
a month ago
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
GuruFocus.com
a month ago
Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ...
Compare MIRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRM Mirum Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.